Overview
RYTM market data
Price History
RYTM price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.02 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.97 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $74.50 – $122.20 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $7.4K · P/B 26.45 · P/S 33.90.
Company News
Rhythm Pharmaceuticals shares are trading higher after JP Morgan initiated coverage on the stock with an Overweight rating and announced a $145 price target.Benzinga · Jul 27, 2026, 6:16 PM
JP Morgan Initiates Coverage On Rhythm Pharmaceuticals with Overweight Rating, Announces Price Target of $145Benzinga · Jul 27, 2026, 11:18 AM
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law FirmGlobenewswire Inc · Jul 17, 2026, 11:15 AM
Rhythm Pharmaceuticals Announces That Results From Its Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide, A Melanocortin-4 Receptor Agonist, In Patients With Acquired Hypothalamic Obesity Have Been Published In The New England Journal Of MedicineBenzinga · Jul 8, 2026, 9:15 PM
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $141Benzinga · Jul 7, 2026, 4:30 PM
Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $151Benzinga · Jun 16, 2026, 4:00 PM
Rhythm Pharmaceuticals Presents Data From Multiple Presentations At Endocrine Society's Annual MeetingBenzinga · Jun 15, 2026, 8:10 PM
8-K filing — RHYTHM PHARMACEUTICALS, INC. (RYTM)SEC EDGAR · Jun 15, 2026, 8:07 PM
Why Is Rhythm Pharma Stock Jumping Today?Benzinga · Jun 15, 2026, 5:15 PM
Wells Fargo Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $155Benzinga · Jun 15, 2026, 1:10 PM